Chemoprophylaxis with chloroquine in a high-risk population for the prevention of SARS-CoV-2 infections severity of infection.

Phase 3

Recruiting

• Conditions: Coronavirus; B04.820.504.540.150

• Registration Number: RBR-7bxhrt
• Lead Sponsor: Instituto René Rachou/FIOCRUZ Minas

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-07-14
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Health professionals attending patients with suspected SARS-CoV-2 infection.
sign the informed consent.
Willing to adhere to the study protocol.

Exclusion Criteria

Known allergy to the study drug (aminoquinolines).
flu-related symptoms at the time of inclusion.
Previous or current SARS-Cov2 infection confirmed.
Known pregnancy (no pregnancy test required).
History of retinopathy.
ECG changes with enlargement of the QT interval.
Weight less than 40 kg
Participant with any immunosuppressive condition or hematological disease.
Treatment with drugs that can prolong the QT interval or increase the number of adverse events in the last month before randomization for more than 7 days, including: azithromycin, chlorpromazine, cisapride, clarithromycin, domperidone, droperidol, erythromycin, halofantrine, haloperidol, lumefantrine, mefloquine, methadone, pentamidine, procainamide, cimetidine, quinidine, quinine, sotalol, sparfloxacin, thioridazine, amiodarone, Dapsone

Study & Design

• Study Type: Intervention
• Study Design: Not specified